Filling and voiding symptoms in the American Urological Association symptom index: The value of their distinction in a veterans affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia

Journal of Urology

Volumn 164, Issue 5, 2000, Pages 1559-1564

  Barry, Michael J ^b   Williford, William O ^b   Fowler Jr , Floyd J ^b   Jones, Karen M ^b   Lepor, Herbert ^b  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b NONE

Author keywords

Health status indicators; Prostate; Prostatic hyperplasia; Urinary tract; Urination disorders

Indexed keywords

FINASTERIDE; TERAZOSIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FACTORIAL ANALYSIS; HEALTH CARE ORGANIZATION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; URODYNAMICS; UROFLOWMETRY;

EID: 0033782470     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)67028-0     Document Type: Article

References (15)

1. New words for old: Lower urinary tract symptoms for 'prostatism'
2. The American Urological Association symptom index for benign prostatic hyperplasia
3. Correlation of the AUA symptom index with urodynamics in patients with suspected benign prostatic hyperplasia
4. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism
5. Correlation between uroflowmetry, prostate volume, postvoid residue, and lower urinary tract symptoms as measured by the International Prostate Symptom Score
6. Correlation between the International Prostatic Symptom score and a pressure-flow study in the evaluation of symptomatic benign prostatic hyperplasia
7. Correlations between pathology, clinical symptoms and the course of the disease
8. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: Findings from the Health Professionals Follow-up Study
9. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia
10. Measuring disease-specific health status in men with benign prostatic hyperplasia
11. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation
12. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response
13. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials
14. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia
15. Filling vs. voiding symptoms as predictors of benign prostatic hyperplasia-related outcomes